62 results about "Alkalinizing agent" patented technology

The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.

The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.

The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.

The invention provides a preparation method of high-stability cross-linked hydroxypropyl starch ether, and relates to the technical field of starch ether processing. The method comprises the following steps: adding water into a starch raw material to prepare starch milk, adding part of an alkalizer, and stirring for activation; raising the temperature to a first temperature, adding the residual alkalizer, and uniformly stirring and mixing; adding an etherifying agent, heating to a second temperature, carrying out first-stage etherification, adding a cross-linking agent after the hydroxypropyl substitution degree DS of the starch reaches 0.10, and carrying out second-stage etherification at the second temperature; and finally, carrying out post-treatment on the etherified product to prepare the cross-linked hydroxypropyl starch ether. According to the cross-linked hydroxypropyl starch ether produced by the method, the problems of local gelatinization and by-product residue of the existing cross-linked hydroxypropyl starch ether are solved, the industrial production of the high-stability food-grade safe hydroxypropyl cross-linked starch ether is realized, and the product better meets the market demand.

The present invention relates to a dry fermentation comprising, per kilogram of dry matter: 4.7 mol to 8.1 mol of a propionate salt; 1.2 mol to 3.0 mol of a calcium cation; 2.4 mol to 7.8 mol of an alkali metal cation selected from the group consisting of sodium, potassium, and combinations thereof; and. 1 g to 50 g of a glucose equivalent weight of hydrolyzed glucan; the calcium cation and the propionate are present in a molar ratio of 0.2 to 0.6 in the dry fermentation. The dried propionate leavening according to the present invention combines a very high propionate content with a light taste. The present invention also provides a method of preparing a dry ferment of the present invention, said method comprising an incubation step in which the pH is maintained in the range of 5.0 to 7.5 by adding an alkalizing agent comprising an alkaline water-soluble alkali metal salt and an alkaline water-soluble calcium salt.

The present invention relates to the technical field related to sodium ion analysis, and discloses an integrated sodium ion concentration analyzer, comprising an integrated cabinet, a detection barrel fixedly installed inside the integrated cabinet, a first pipe connected to the top of the detection barrel, a first control valve provided on the first pipe, a pH sensor fixedly installed inside the detection barrel, and an adjustment mechanism provided inside the detection barrel. The present invention can move a conical plug to different positions of an infusion tube port as needed, can change the flow rate of an alkalizing agent in the infusion tube port, and conveniently control and adjust the delivery rate of the alkalizing agent; in addition, the alkalizing agent inside a plurality of drainage pipes will be respectively delivered to different positions inside the adjustment barrel, and when the alkalizing agent contacts and mixes with the solution, the output end of the first motor will drive the agitator to rotate, and the plurality of drainage pipes outside the agitator will act as the stirring blades of the agitator and stir the mixed solution and the alkalizing agent, so that the solution and the alkalizing agent can quickly mix and react and adjust the pH value of the solution.

The present invention provides a pharmaceutical composition for treating or preventing peripheral nerve disorders induced by chemotherapeutic drugs, comprising an alkalizing agent. By administering this pharmaceutical composition, peripheral nerve disorders induced by chemotherapeutic drugs, particularly chemotherapeutic drugs for cancer, can be treated or prevented. Also provided is an anticancer pharmaceutical composition for inhibiting the expression of peripheral nerve disorders, the anticancer pharmaceutical composition comprising an alkalizing agent and a cancer chemotherapeutic agent. The administration of this pharmaceutical composition makes it possible to treat cancers in which the expression of peripheral nerve disorders can be suppressed.

The application belongs to the technical field of starch chemical modification, and particularly relates to a preparation method of acetylated distarch phosphate. The method comprises the following steps: mixing starch with a deep eutectic solvent composed of choline chloride, glycerol and a small amount of water, adding a phosphate crosslinking agent and a delayed-release alkalizing agent for crosslinking reaction after pH adjustment, performing acetylation reaction by adding acetic anhydride or vinyl acetate after cleaning by alcohol solvent replacement, and finally obtaining the product through neutralization, washing, dehydration and drying. The process utilizes the deep eutectic solvent to control water activity and particle structure, and combines the slow-release alkali source to maintain a stable reaction environment, so that the crosslinking and acetylation are uniformly carried out, and the side reactions and residual salt load are effectively reduced. The obtained acetylated distarch phosphate has stable substitution degree, uniform particle structure and excellent performance in freeze-thaw stability, and is suitable for multiple fields such as papermaking, textile and oil field additives.

The application discloses a kind of air cooling island flow accelerated corrosion simulation test system and method, main loop subsystem, including high-purity water tank, main loop outlet pipe, electrode flow cell and main loop return pipe;The water outlet of high-purity water tank is connected with the one end of main loop outlet pipe, the other end of main loop outlet pipe is connected with the water inlet of electrode flow cell, the one end of main loop return pipe is connected with the water outlet of electrode flow cell, the other end of main loop return pipe is connected with the backwater of high-purity water tank;Dosing subsystem is used to add alkali agent or oxidizing agent to main loop outlet pipe;Flow accelerated corrosion test subsystem includes test electrode and corrosion tester;Test electrode is placed in electrode flow cell, and test electrode is connected with the input end of corrosion tester by wire;The material of test electrode is the same as the material of the equipment to be simulated air cooling island;The application realizes the real simulation of air cooling island equipment, meets the simulation of high flow rate and anaerobic condition, and the error of simulation test result is small.

The invention discloses a dust suppression material based on calcium slow-release crosslinking. The dust suppression material comprises 2-6 parts of xylan, 9-85 parts of sodium chloroacetate, 0.12-0.85 part of calcium chloride, 0.6-1 part of citric acid, 1-2 parts of ethyl lactate, 24-56 parts of a basifier, 1-9 parts of a wetting agent and 1500-3000 parts of distilled water. Xylan is modified through carboxymethylation reaction, a calcium slow-release system is constructed to control the release rate of Ca < 2 + >, slowly released Ca < 2 + > is wrapped by carboxyl of adjacent xylan chains to form local crosslinking points, Ca < 2 + > serves as a molecular bridge, and linear molecular chains are connected into a stable three-dimensional network; the prepared dust suppression material has high wetting and permeability, high bonding strength, high water-retaining property, high environmental durability and a long-acting dust suppression effect.

Methods are disclosed herein for producing ester derivatives of alpha-glucan comprising alpha-1,6 linkages. Such methods can comprise esterifying an alkalized alpha-glucan in an esterification reaction composition that otherwise does not contain any added alkalizing agent. Further disclosed are alpha-glucan ester compositions produced by the disclosed processes, as well as various applications of using these compositions.

The present invention relates to an oral pharmaceutical composition comprises semaglutide, SNAC (Sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), one or more alkalizing agent and one or more pharmaceutically acceptable excipients.

The present invention provides a pharmaceutical composition for treating an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, the pharmaceutical composition comprising an alkalizing agent. By administering this pharmaceutical composition, it is possible to treat an acute-phase peripheral neuropathy induced by a chemotherapeutic agent, in particular, a chemotherapeutic agent for cancer. The present invention also provides an anticancer pharmaceutical composition that contains an alkalizing agent and a chemotherapeutic agent for cancer and that is designed to suppress an acute-phase peripheral neuropathy induced by the chemotherapeutic agent or to suppress worsening of symptoms caused by the peripheral neuropathy. By administering this pharmaceutical composition, it is possible to provide a cancer treatment in which an acute-phase peripheral neuropathy or worsening of symptoms caused by the peripheral neuropathy is suppressed.

A composition for treating dentin hypersensitivity, comprising: a first component comprising: (i) a first rheology modifying polymer; (ii) a calcium ion source; (iii) a positively charged basic amino acid; and (iv) an acidifying agent, wherein the first component has a pH in the range of about 2.0 to about 7.0; a second component comprising: (i) a second rheology modifying polymer; (ii) a phosphate ion source; and (iii) an alkalizing agent, wherein the second component has a pH in the range of about 7.0 to about 14.0; wherein the first component and the second component are combined into a mixture such that a cationic amorphous calcium phosphate gel composition is created instantly when the pH of the mixture reaches a pH range of about 7.0 to about 9.5.

A hydraulic binder including (in % by dry weight); A. at least 50 of at least one ground and granulated blast-furnace slag; B. more than 5 of at least one calcium aluminate cement and / or of at least one calcium sulfoaluminate cement; C. more than 5 of at least one source of sulfate ions; D. between 1 and 5 of Ca(OH)2 and / or Portland cement; E. between 0.01 and 1 of at least one alkali metal carbonate; F. and at least one alkalifying reagent consisting of at least one alkali metal carbonate and / or bicarbonate, different from E; under the following conditions: (i) amount of C allows sulfate ions of C to react with B and A; (ii) the amount of F sufficiently causes a reaction with D in water resulting in a wet formulation with a pH not less than 12, for a water-to-mortar mixing rate between 10 and 35% by weight.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

The present invention relates to a proprietary encapsulation technology where in a composition comprising mangiferin will maintain in-situ alkaline environment and minimizes the precipitation issues of mangiferin in the acidic environment. A composition of mangiferin has been disclosed. A natural hydrophilic plant-based carrier along with a selected alkalizer is being embedded in the encapsulation matrix which subsequently acts as a platform to ensure the alkaline environment with better solubility of bioactive across the physiological pH range.

The invention provides a rapid evaluation method for the chain segment characteristics of ethyl cellulose, which comprises the following steps: preparing an EC emulsion from an ethyl cellulose sample to be detected, and determining the chain segment characteristics of ethyl cellulose by measuring the parameters of the EC emulsion. The detection parameters of the EC emulsion product comprise the ethyoxyl content, the emulsion peak number, the average particle size and the particle size distribution. The preparation method of the EC emulsion comprises the following steps: S1, crushing and sieving an ethyl cellulose sample for later use; s2, placing the ethyl cellulose undersize product in a reactor, sequentially adding a plasticizer and a solvent into the reactor while stirring, and dispersing to obtain an oil-phase intermediate; and S3, adding an emulsifier and an alkalizer into the oil-phase intermediate, and adding the oil-phase intermediate into distilled water for multiple times under high-shear dispersion to obtain the EC emulsion to be detected. According to the method, the emulsification technology is applied to determination of EC chain segment distribution characteristics for the first time, the method has good applicability and universality, the whole detection process is efficient and rapid, data reliability is enhanced, and application predictability is accurate.

Compositions and methods are disclosed herein for inducing (up-regulating) the expression of sulfotransferases in the hair follicles, e.g., the scalp. Increasing sulfotransferase is beneficial for metabolizing pro-drugs that require sulfonation to be activated, e.g., minoxidil sulfate is the active metabolite of minoxidil. A method for combining the compositions described herein with topical minoxidil to enhance minoxidil treatment for androgenetic alopecia is described. Additional methods and compositions include the use of retinoid X receptor agonists, retinoic acid receptor agonists, and nuclear receptor agonists in an RXR-NR heterodimer. Additional methods and compositions include the use of a topical solution containing an alkalinizing agent or an alkalinizing agent used with a penetration enhancer for up-regulating the sulfonating capacity of hair bearing skin, hair follicles, and / or keratinocyte cells. In addition, compositions and methods for increasing or decreasing the growth rate of hair follicles is disclosed by altering the intracellular pH. Additionally, methods for preparing a stable liposomal containing solution are described.

Provided are water for treating seafood, a method for producing the same, and a method for producing seafood whose freshness is maintained. [Solution] Seafood processing water contains electrolyzed water and an alkalizing agent, and has a pH greater than 7.0 and not greater than 10.5. The alkalizing agent is added to acidic electrolyzed water to produce seafood processing water with a pH greater than 7.0 and not greater than 10.5. By applying this seafood processing water to seafood, seafood that has been kept fresh can be produced.

The present invention is to provide an amorphous solid dispersion comprising elacestrant dihydrochloride of formula (I), in combination with one or more pharmaceutically acceptable excipients such as a stabilizing agent including a polymer and / or an alkalizing agent. Additionally, the invention provides a process for the preparation of such amorphous solid dispersions and an amorphous form of elacestrant dihydrochloride. The resulting amorphous form or amorphous solid dispersions are advantageous for the formulation of pharmaceutical dosage forms and compositions, enhancing the bioavailability and stability of elacestrant dihydrochloride.

The invention discloses a preparation method and application of a polyferric sulfate flocculant, and relates to the technical field of industrial waste liquid recycling and sewage treatment. A sulfuric acid replacement method is combined with a negative pressure evaporation method to recover hydrochloric acid in waste liquid, the ratio of chloride ions to sulfate radicals is regulated and controlled, an alkalizer is added into evaporation mother liquor to be heated and dissolved, then oxidizing gas is introduced for oxidation, and red brown liquid, namely the flocculating agent, is prepared after hydrolytic polymerization. The raw materials are wide in source and low in price and cost, special complex operation is not needed in the preparation process, and the preparation method is suitable for industrial production; the prepared polyferric sulfate chloride is applied to phosphorus-containing sewage treatment, and the treatment efficiency is extremely high.

The invention belongs to the technical field of chemical modification of starch, and particularly relates to a preparation method of acetylated distarch phosphate. The method comprises the following steps: mixing starch with a deep eutectic solvent consisting of choline chloride, glycerol and a small amount of water, adjusting the pH value, adding a phosphate radical crosslinking agent and a delayed release basifier to carry out a crosslinking reaction, replacing and cleaning with an alcohol solvent, adding acetic anhydride or vinyl acetate to carry out an acetylation reaction, and carrying out vacuum drying to obtain the modified starch. And finally neutralizing, washing, dehydrating and drying to obtain the product. According to the process, the water activity and the particle structure are regulated and controlled by utilizing the deep eutectic solvent, a stable reaction environment is maintained by combining a slow-release alkali source, uniform proceeding of crosslinking and acetylation is realized, and side reaction and residual salt load are effectively reduced. The obtained acetylated distarch phosphate is stable in substitution degree, uniform in particle structure, excellent in freeze-thaw stability and the like, and suitable for multiple fields such as papermaking, spinning and oilfield auxiliaries.

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75% ± 2% by weight cyclobenzaprine HCl and 25% ± 2% by weight β‑mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

A cosmetic product, containing a composition A including one or more alkalizing agents, an aqueous composition B having a pH in a range of 1 to 6 and containing one or more oxidizing agents, and a composition C containing one or more compounds selected from the following groups:1)where R1, R2, and R3 are independently selected from H and CH3,2) one or more orthodiphenols and salts thereof, and3) one or more imidazolidin-2,4-diones and salts thereof.

The application provides a nano cerium dioxide-based fuel additive and a preparation method and application thereof. The preparation method of the nano cerium dioxide-based fuel additive comprises the following steps: mixing a ligand, a dispersing agent, a dissolving oil and an oil phase auxiliary agent to obtain an oil phase; mixing cerium halide, an aqueous phase solvent, an oxidizing agent and an alkalizing agent to obtain an aqueous phase; and reacting the oil phase and the aqueous phase by using a supergravity reaction method to obtain the nano cerium dioxide-based fuel additive. The nano cerium dioxide-based fuel additive can be stably dispersed in fuel.

The present invention relates to a dyeing product for keratin fibres, preferably human keratin fibres, more preferably human hair, characterized in that said dyeing product comprises at least a composition A and a composition B, composition A comprising: a) one or more hair direct dyes, and b) one or more alkalizing agents; the composition B is a water-based composition, the pH range of the composition B is 1-6, and the composition B comprises c) one or more ammonium salts with the following general formula: NH4 < + > Y <->, and in the formula, Y <-> is anions except OH <-> and CO3 < 2->; wherein the total concentration of the oxidant in the composition B is less than 1 wt%, preferably less than 0.1 wt%, and more preferably, the composition B does not contain the oxidant based on the total weight of the composition B.

This invention relates to the field of biomedical technology, and more particularly to a fenelazol microsphere, its preparation method, and capsules. This invention optimizes the formulation of the original fenelazol tablets, using blank pellet cores as a carrier, sodium carbonate as an alkalizing agent, and sulfobutyl-β-cyclodextrin as an excipient to prepare fenelazol microsphere capsules. Experiments show that these microspheres have excellent solubility in gastric acid, are pH-independent, and exhibit high long-term storage stability. This invention simplifies the production process, has good process stability, low production costs, and is suitable for large-scale production.

The application relates to a treatment method of hydrometallurgical raffinate, which comprises the following steps: performing a fractional co-precipitation reaction on the raffinate by using characteristic seeds in the presence of an alkalizing agent until the heavy metal content in the raffinate is less than 10 mg / L and the COD is less than 300 mg / L. The treatment method provided by the application recycles the characteristic seeds as renewable resources, can realize synchronous removal of organic matters and heavy metal ions in the raffinate wastewater and resource recovery, the COD of the raffinate effluent is less than 300 mg / L, the concentration of heavy metal ions is less than 10 mg / L, the heavy metal recovery rate is more than 98%, the hydraulic retention time is short, the turbidity of the effluent is small, no sludge is produced, no secondary pollution is caused, and the cost is effectively reduced.

The present invention relates to a process and mixture for the safe dosing of a sulfidizing agent in a mineral flotation process that comprises the prior preparation of a mixture of sulfidizing agent with at least one alkalizing agent. In this way, the production of hydrogen sulfide is prevented, allowing the mixture to be safely used in mining operations located in enclosed places such as caves or in operations close to populated areas.